Loading news...
Recursion Pharmaceuticals (RXRX) reached $4.32 at the closing of the latest trading day, reflecting a -3.36% change compared to its last close.
DraftKings' bulls were thrown an unexpected curveball, but this new competition doesn't carry the same brand-name cache. After years of development, Recursion Pharmaceuticals' AI-powered drug discovery technology should finally, firmly start proving its true value.
Recursion Pharmaceuticals lagged the market last year. The stock doesn't have significant catalysts on the horizon.
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Baillie Gifford and Co. lowered its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 0.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,978,695 shares of the company's stock after selling 195,120 shares during the quarter. Baillie Gifford and
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.73, representing a -4.64% change from its previous close.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
Tech giants Meta Platforms and Apple are capitalizing on their AI-related efforts. However, biotech upstart Recursion Pharmaceuticals' initiatives have yet to pay off.
Recursion Pharmaceuticals (RXRX) closed at $4.65 in the latest trading session, marking a -4.12% move from the prior day.
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) have received a consensus rating of "Hold" from the six analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) CFO Ben Taylor sold 21,383 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $4.18, for a total transaction of $89,380.94. Following the transaction, the chief financial officer directly owned 761,550 shares in the company, valued
Bank Pictet and Cie Europe AG bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,630,000 shares of the company's stock, valued at approximately $7,954,000. Bank Pictet
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) insider Najat Khan sold 124,403 shares of the firm's stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $4.41, for a total transaction of $548,617.23. Following the sale, the insider owned 611,135 shares in the company, valued
Wall Street is ending 2026 on a generally positive note, with the benchmark S&P 500 Index set to finish the year at a 17% return rate. All eyes are now on technology titans like Nvidia, Microsoft, Alphabet, and Amazon, which have dominated the headlines in 2025, and for good reason.
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Cathie Wood's ARK Invest once again trimmed its stake in Tesla (TSLA) while increasing exposure to crypto-related stocks, according to a Thursday filing with th
Recursion Pharmaceuticals, Inc. is upgraded to Buy, supported by promising REC-4881 data and strong institutional backing. REC-4881's Phase 1b/2 data in FAP show a 43% median polyp reduction, derisking the lead program ahead of pivotal studies. RXRX's $2.44bn market cap is justified by FAP opportunity, robust partnerships, and over $100m in milestone payments expected by end-2026.
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However, here's a reality check: RXRX remains down by 35% year-to-date and is trading below $5.